Company news

Orthocell Ltd news in 2024

Orthocell Ltd's news releases, calls and decks from 2024, newest first.

View company

US FDA Application Submitted for Remplir as US Launch Nears

December 18, 2024

Major Milestone with First Sales of Remplir in Singapore

December 11, 2024

Outstanding Remplir Study Results Pave Way for FDA Clearance

December 1, 2024

Distributor Signed, Remplir Sales in Singapore to Commence

November 26, 2024

Key Executives Appointed to Drive Remplir US Sales

November 10, 2024

Orthocell completes $17m Placement

October 30, 2024

$17m Placement to Drive Further Growth as US Approval Nears

October 24, 2024

Regulatory approval to commence Remplir sales in Singapore

October 7, 2024

Second Consecutive Record Quarter as Revenue Exceeds $2m

October 6, 2024

First sales of Striate in major new market of Canada

September 5, 2024

Company Presentation

August 29, 2024

Regulatory Approval to Commence Sales for Striate in Canada

July 10, 2024

Record Quarterly and Yearly Revenue Show Outstanding Growth

July 8, 2024

Third Revenue Generating Product to be Launched in SmrtGraft

June 10, 2024

Orthocell reports 98.6% success rate in Striate+â„¢ dental membrane study

May 15, 2024

Outstanding 98.6% Success Rate in Striate Implant Study

May 13, 2024

Orthocell receives $3.05m R&D tax incentive refund

April 14, 2024

Part 1 Remplir US Market Authorisation Successfully Complete

March 24, 2024

Appendix 4D & Half-Year Financial Statements

February 23, 2024

Strategic Placement to Raise $3.5 million

February 21, 2024

Remplir Expansion Continues with Singapore Application

February 12, 2024

Decks in 2024